Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

First therapeutic device developed within the Institute of Biomedical Engineering (IBME) and the Nuffield Department of Surgical Sciences (NDS) completes regulatory approval on both sides of the Atlantic.

Preserving livers at body temperature has been shown to improve transplant success and to increase the number of viable donor livers available for transplant.
David Nasralla and Annemarie Weissenbacher, both transplant surgeons who recently completed their DPhil at NDS, operate the OrganOx metra during the COPE clinical trial

University spin-out OrganOx, a world leader in normothermic machine perfusion (NMP), recently announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) of its metra system. The metra is the first medical device to have emerged from research carried out in IBME and NDS at Oxford University. 

The OrganOx metra is a fully automated NMP device for the preservation and transport of donor livers destined for transplantation. The FDA marketing approval includes both livers from donors after brain death (DBD) and livers from donors after circulatory death (DCD) and is expected to greatly increase the number of organs available for liver transplantation in the United States.

The device is already CE-marked and has received a positive NICE recommendation in the UK, where it has been widely used since 2018, following on from a randomized clinical trial sponsored by the University of Oxford and published as a cover story in Nature in May 2018.

Resulting from cross-disciplinary biomedical engineering research at the University of Oxford’s Department of Engineering Science and NDS, with trials supported by the NIHR and EU, the OrganOx metra is the world’s first normothermic (i.e. normal body temperature) organ preservation device used for improved and prolonged preservation and functional testing of livers prior to transplantation.

Led by Professors Constantin Coussios FREng and Peter Friend FMedSci, this device was developed over the course of 15 years of research and it is the first to enable prolonged preservation of an organ in a functioning state outside the body. This makes it possible to (i) preserve organs for at least twice as long as conventional cold preservation techniques; (ii) assess the function of the graft during preservation before putting the recipient at risk; and (iii) safely use livers available within current donation practices that are currently perceived as being too risky for transplant, including fatty livers and organs from donors following circulatory death. It enables the safe utilisation of over 70% of livers which were until recently deemed unsuitable for transplant and makes it possible for hospitals to perform the majority of their transplants as a planned daytime procedure. 

After commercialisation, the OrganOx metra is today deployed and routinely used in all seven UK liver transplant centres with impressive early results, seeing an increase in annual liver transplant numbers within current donation practice. In 2019 OrganOx won the Medtech Insight Award for “best Proof-of-Value of an Innovation”, recognising the benefits of its normothermic perfusion platform in increasing the utilisation of donated organs.

Craig Marshall, OrganOx CEO, commented: 'We are thrilled with this news and excited to be able to bring our technology to the US, which we expect will increase the utilization of donor organs and thereby reduce waitlist mortality.  To date, the metra has supported more than 1,200 liver transplants worldwide, with several individual centres in Europe having transplanted more than 100 donor livers using our system.

There is a clear unmet clinical need for our device in the US where the situation is similar to Europe, with many patients dying on the waitlist and large numbers of donated organs that are not transplanted. With our device we aim to make more livers available for transplantation to ensure that more patients can benefit from this life saving procedure.'

Dr Stuart Knechtle, Executive Director of the Duke Transplant Center at Duke University School of Medicine and National Principal Investigator for the IDE Trial that supported PMA approval added: 'Through the IDE Trial we have seen the difference this technology can make to liver transplant outcomes. The biggest benefit of the metra is the ability to assess the function of the organ on the device, prior to committing to the transplant. This offers the potential to safely expand the pool of donor organs which would result in many more US patients receiving a liver transplant.'

Similar stories

NDS projects awarded CRUK Oxford Cancer Development Fund

Two research projects at the Nuffield Department of Surgical Sciences (NDS) have been awarded pump-prime funding from this year’s CRUK Oxford Centre Development Fund.

Study finds higher risk of all-cause mortality among paediatric cancer patients in LMICs during the pandemic

During the first nine months of the COVID-19 pandemic, paediatric cancer patients from lower- and middle-income countries (LMICs) faced a higher risk of all-cause mortality than those in high-income countries, according to an international study led by the University of Oxford.

Study reveals that bone changes energy requirements of cancer cells to promote growth and survival

Interrogating metabolic cross-talk in the tumour-bone microenvironment, new research from the Edwards Group shows how the pentose phosphate pathway contributes to prostate cancer bone metastasis.

First-in-human implant of a “closed-loop” bioelectronic research system for investigating treatments for brain disorders

Researchers at Oxford University have implanted a novel closed-loop research platform for investigating the role of the pedunculopontine nucleus (PPN) – a brainstem nucleus – in Parkinson’s-like Multiple Systems Atrophy (MSA).

Oxford team publish blueprint for making millions of doses of a new vaccine within 100 days

The University of Oxford’s vaccine manufacturing research team has today published a pre-print paper demonstrating the feasibility of a step change in the speed and volume of production of adenovirus-vectored vaccines against new virus variants or other future pandemics.

Dr Matthew Bottomley wins Stewart Cameron Science Award

Congratulations to Dr Matthew Bottomley, who has been announced as the joint winner of the Stewart Cameron Science Award by the Royal Society of Medicine (RSM).

Blog posts

Lights, camera, action! My journey into video production

Dr Hannah McGivern provides a 'behind-the-scenes' account of her experience producing the video 'Journey of a QUOD Sample: Donating to Transplant Research', supported by the funds from the University of Oxford Public Engagement with Research (PER) Seed Fund.

Mentoring in practice

NDS has launched a new, interdepartmental mentoring scheme called RECOGNISE. In this podcast, Gemma Horbatowski (HR Advisor) interviews Monica Dolton (Programme Manager and Research Project Manager) about her experiences of mentor-mentee relationships.

Wrap up of 2021

After a brilliant year of hard work and dedication, the SITU team has done some reflection on 2021, focusing on key events, trial progression, and more. Read on to discover how the year 2021 went for the SITU team...

Celebrating Anti-Bullying Week with words of kindness

Keeva Heap, who is undertaking a communications work experience placement at the Nuffield Department of Surgical Sciences (NDS), shares our words of kindness In honour of Anti-Bullying Week.

My virtual work experience with NDS and NDORMS

Louise Tan, a Year 12 student from Ballyclare in County Antrim, Northern Ireland, recently attended the joint NDS and NDORMS Virtual Work Experience. In this guest blog, Louise reflects on her experience.